目的 探究黄豆苷元联合戊酸雌二醇片雌二醇环丙孕酮片复合包装治疗围绝经期综合征患者的临床效果。方法 选取2016年7月—2017年7月东营市第二人民医院收治的围绝经期综合征患者140例，随机分成对照组（70例）和治疗组（70例）。对照组患者口服戊酸雌二醇片/雌二醇环丙孕酮片复合包装，1片/次，1次/d，连续治疗21 d后停药7 d为1个疗程；治疗组患者在对照组的基础上口服黄豆苷元片，1片/次，3次/d。两组患者均连续治疗3个疗程。观察两组患者临床疗效，同时比较治疗前后两组患者体内激素水平、KMI评分、子宫内膜厚度和不良反应情况。结果 治疗后，对照组临床有效率为84.29%，显著低于治疗组的95.97%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者雌二醇水平显著升高（P<0.05），卵泡刺激素水平显著降低（P<0.05），且治疗后治疗组患者雌二醇和卵泡刺激素水平明显优于对照组（P<0.05）。治疗后，两组患者KMI评分显著降低（P<0.05），子宫内膜厚度显著升高（P<0.05），且治疗后治疗组患者KMI评分和子宫内膜厚度明显优于对照组（P<0.05）。治疗期间，对照组不良反应发生率为15.71%，明显高于治疗组的4.28%，两组比较差异具有统计学意义（P<0.05）。结论 黄豆苷元联合戊酸雌二醇片雌二醇环丙孕酮片复合包装治疗围绝经期综合征患者临床有效率高，不良反应率低，具有一定的临床推广应用价值。

Objective To explore the clinical effects of c Daidzein Tablets combined with Complex Packing Estradiol Valerate Tablets, Estradiol Valerate and Cyproterone Acetate Tablets in treatment of menopause syndrome. Methods Patients (140 cases) with menopause syndrome in the Second People's Hospital of Dongying from July 2016 to July 2017 were randomly divided into control (70 cases) and treatment (70 cases) groups. Patients in the control group were po administered with Complex Packing Estradiol Valerate Tablets, Estradiol Valerate and Cyproterone Acetate Tablets, 1 tablet/time, once daily, continuous course treatment for 21 d and then withdrawal for 7 d was a course of treatment. Patients in the treatment group were po administered with Daidzein Tablets on the basis of the control group, 1 tablet/time, three times daily. Patients in two groups were treated for 3 courses of treatment. After treatment, the clinical efficacy was evaluated, and the hormones levels, the KMI scores, endometrial thickness and the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 84.29%, which was significantly lower than 95.97% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the estradiol levels in two groups were significantly increased (P < 0.05), but the follicle stimulating hormone levels were significantly decreased (P < 0.05), and the estradiol and follicle stimulating hormone levels in the treatment group after treatment were significantly better than those in the control group (P < 0.05). After treatment, the KMI scores in two groups were significantly decreased (P < 0.05), but the endometrial thickness was significantly increased (P < 0.05), and the KMI scores, endometrial thickness in the treatment group after treatment were significantly better than those in the control group (P < 0.05). During the treatment, the adverse reactions rate in the control group was 15.71%, which was significantly higher than 4.28% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion Daidzein Tablets combined with Complex Packing Estradiol Valerate Tablets, Estradiol Valerate and Cyproterone Acetate Tablets has high effect in treatment of menopause syndrome with low adverse reactions rate, which has a certain clinical application value.